



**The Drug Utilization Review Board Reviewed the Following
New Drugs and Supplemental Rebate Classes on
June 6, 2013**

The Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drugs and classes for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL).

New Drug Reviews

Multiple Sclerosis Agent

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Aubagio™ (Oral) Tablet*.

Antineoplastic

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Bosulif™ (Oral) Tablet*.

Irritable Bowel Syndrome – Constipation

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Linzess™ (Oral) Capsule*.

Antispasmodic

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Myrbetriq™ (Oral) Tablet Extended-Release*.

Antineoplastic

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Stivarga™ (Oral) Tablet*.

Antineoplastic

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Synribo™ (Subcutaneous) Vial*.

Chronic Obstructive Pulmonary Disorder Inhaler

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Tudorza™ (Inhalation)*.

Biologic Immunomodulator

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Xeljanz™ (Oral) Tablet*.

Class Reviews

The following classes were reviewed with recommendations for changes in PDL status for the following drugs.

Anaphylaxis Therapy

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Auvi-Q® (Injection) Auto*



Injector.

Angiotensin Converting Enzyme Inhibitors and Combinations

The DUR Board recommended *Preferred* status for *Amlodipine-Benazepril (Oral) Capsule* and *Non-Preferred* status with *Prior Authorization* for *Lotrel[®] (Oral) Capsule*.

Antidepressants – Selective Serotonin Reuptake Inhibitors

The DUR Board recommended *Preferred* status for *Escitalopram Oxalate (Oral) Solution* and *Non-Preferred* status with *Prior Authorization* for *Lexapro[®] (Oral) Solution*.

Antifungals – Oral

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Griseofulvin (Oral) Microsize Tablet*.

Antispasmodics

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Trospium Chloride (Oral) Tablet*.

Atypical Antipsychotics – Long-Acting Injectables

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Abilify[®] Maintena[®] (Intramuscular) Vial* and that the prior authorization criteria should be at parity to other atypical antipsychotic long-acting injectables.

Betalactam-Clavulanate Combinations

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Amoxicillin Trihydrate-Potassium Clavulanate (Oral) Tablet 250mg-125mg* and *Augmentin[®] (Oral) Suspension for Reconstitution 250mg-62.5mg/5mL*.

Calcium Channel Blockers

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Isradipine (Oral) Capsule*, *Nicardipine Hydrochloride (Oral) Capsule* and *Verapamil Extended-Release PM (Oral) Capsule 24 Hour*.

Chronic Obstructive Pulmonary Disorder Inhalers

The DUR Board recommended *Preferred* status for *Combivent[®] Respimat[®] (Inhalation)*.

Contraceptives – Emergency

The DUR Board recommended *Preferred* status for *Next Choice[®] One Dose (Oral) Tablet*, and *Non-Preferred* status with *Prior Authorization* for *Ella[®] (Oral) Tablet*, *Levonorgestrel (Oral) Tablet* and *Next Choice[®] (Oral) Tablet*.

Diabetic – Oral

The DUR Board recommended *Preferred* status for *Starlix[®] (Oral) Tablet* and *Non-Preferred* status with



Prior Authorization for *Chlorpropamide (Oral) Tablet*, *Fortamet® (Oral) Tablet Extended-Release*, *Tolazamide (Oral) Tablet* and *Tolbutamide (Oral) Tablet*.

Gastrointestinal – Antiulcer Antiinfectives

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Prevpac® (Oral) Combination Package* and *Pylera® (Oral) Capsule*.

Gastrointestinal – Digestive Enzymes

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Pancreaze® (Oral) Capsule Delayed-Release with grandfathering and a request for expert consultation in the future*.

Herpes Agents – Oral

The DUR Board recommended *Preferred* status for *Valacyclovir (Oral) Tablet* and *Non-Preferred* status for *Valtrex® (Oral) Tablet*.

Ophthalmic – Miscellaneous

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Neomycin-Polymyxin B-Hydrocortisone (Ophthalmic) Drops Suspension*.

Prenatal Vitamins

The DUR Board recommended *Preferred* status for *Citranatal® DHA Products* and *Non-Preferred* status with *Prior Authorization* for *DHA Products That Cost More Than \$26 Per Claim*.

Topical – Antipsoriatics

The DUR Board recommended *Preferred* status for *Calcipotriene (Topical) Solution* and *Non-Preferred* status with *Prior Authorization* for *Dovonex® (Topical) Solution*.

Topical – Antivirals

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Denavir® (Topical) Cream*.

Topical – Genital Warts

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Veregen® (Topical) Ointment*.

Urinary Antiinfectives

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Urelle® (Oral) Tablet*.

The recommendations on the drugs in the following classes reviewed remained the same as the current PDL status, which is located at http://dch.georgia.gov/00/channel_title/0,2094,31446711_32050640,00.html.

Beta Adrenergics – Short-Acting Nebulizers

Contraceptives – Biphasic – Oral



Contraceptives – Progestins – Oral

Contraceptives – Triphasic – Oral

Cough and Cold Products

Drugs for Gout

Fluoroquinolones – Oral

Glucocorticoids – Oral

Hemostatics

Immunosuppressants

Leukotriene Modifiers

Sedative Hypnotics

The DUR Board also recommended a study be conducted comparing zolpidem to other sedative hypnotics.

Statins

Topical – Enzymes

Topical – Local Anesthetics